Inpharma 1100 - 16 Aug 1997 Warfarin: no additional benefit over aspirin alone post-MI Low-dose warfarin plus aspirin offers no clinical benefit over aspirin monotherapy in patients who have recently experienced an acute myocardial infarction (MI), report the CARS * investigators from the US and Canada. Patients who had experienced an acute MI 3–21 days previously were followed in this multicentre study. ** They were randomised to receive aspirin 160 mg/day (n = 3393), warfarin 1mg plus aspirin 80 mg/day (2028) or warfarin 3 mg/day plus aspirin 80 mg/day (3382) If necessary, warfarin dosages were adjusted according to the international normalised ratio. Study discontinued prematurely The median duration of follow-up was 14 months; the study was discontinued prematurely on the advice of the data and safety monitoring committee when analysis of the study data revealed no significant difference in outcome between the 3 study groups. The relative risk of a primary event (non-fatal reinfarction, non-fatal ischaemic stroke or cardiovascular death) was 0.95 in the aspirin monotherapy recipients compared with warfarin 3mg plus aspirin recipients, 1.03 in the aspirin monotherapy recipients compared with the warfarin 1mg plus aspirin recipients, and 0.93 in the warfarin 1mg plus aspirin recipients compared with the warfarin 3mg plus aspirin recipients. * Coumadin Aspirin Reinfarction Study ** This study was funded by Du Pont Merck. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double- blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 350: 389-396, 9 Aug 1997 800555024 1 Inpharma 16 Aug 1997 No. 1100 1173-8324/10/1100-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Warfarin: no additional benefit over aspirin alone post-MI

Download PDF Report

View
220
Download
1

Embed Size (px)

Citation preview

Inpharma 1100 - 16 Aug 1997

Warfarin: no additional benefit overaspirin alone post-MI

Low-dose warfarin plus aspirin offers no clinicalbenefit over aspirin monotherapy in patients who haverecently experienced an acute myocardial infarction(MI), report the CARS* investigators from the US andCanada.

Patients who had experienced an acute MI 3–21 dayspreviously were followed in this multicentre study.**

They were randomised to receive aspirin 160 mg/day (n= 3393), warfarin 1mg plus aspirin 80 mg/day (2028) orwarfarin 3 mg/day plus aspirin 80 mg/day (3382) Ifnecessary, warfarin dosages were adjusted according tothe international normalised ratio.

Study discontinued prematurelyThe median duration of follow-up was 14 months; the

study was discontinued prematurely on the advice of thedata and safety monitoring committee when analysis ofthe study data revealed no significant difference inoutcome between the 3 study groups.

The relative risk of a primary event (non-fatalreinfarction, non-fatal ischaemic stroke orcardiovascular death) was 0.95 in the aspirinmonotherapy recipients compared with warfarin 3mgplus aspirin recipients, 1.03 in the aspirin monotherapyrecipients compared with the warfarin 1mg plus aspirinrecipients, and 0.93 in the warfarin 1mg plus aspirinrecipients compared with the warfarin 3mg plus aspirinrecipients.* Coumadin Aspirin Reinfarction Study** This study was funded by Du Pont Merck.

Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction.Lancet 350: 389-396, 9 Aug 1997 800555024